$Jyong Biotech(MENS)$ Ok have done a wee bit more reasearch, found their data release for the trial results. No statistically significant improvement on primary endpoints, the treatment contains non-patentable botanicals that anyone can go out and buy, and all the shit about high insider ownership, tiny IPO, sketchy clinical trial shit, and ridiculus 5 billion dollar valuation are still true.
I would not buy this company at 100m, let along 5 billion, would short this but short borrow rate is >100%, stay away.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments